MA30309B1 - NOUVELLE PROTEINE DE HAEMOPHILUS INFLUENZAE A SURFACE EXPOSEE (PROTEINE; pE) - Google Patents

NOUVELLE PROTEINE DE HAEMOPHILUS INFLUENZAE A SURFACE EXPOSEE (PROTEINE; pE)

Info

Publication number
MA30309B1
MA30309B1 MA31171A MA31171A MA30309B1 MA 30309 B1 MA30309 B1 MA 30309B1 MA 31171 A MA31171 A MA 31171A MA 31171 A MA31171 A MA 31171A MA 30309 B1 MA30309 B1 MA 30309B1
Authority
MA
Morocco
Prior art keywords
protein
exposed surface
haemophilus influenzae
relates
nucleic acid
Prior art date
Application number
MA31171A
Other languages
English (en)
Inventor
Arne Forsgren
Kristian Riesbeck
Original Assignee
Arne Forsgren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arne Forsgren filed Critical Arne Forsgren
Publication of MA30309B1 publication Critical patent/MA30309B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une protéine à surface exposée (protéine E;pE), un facteur de virulence, qui peut être détecté dans Haemophilus influenzae, comprenant une séquence d'acides aminés décrite dans SEQ ID NO 1, un fragment immunogène de ladite protéine à surface exposée, et une protéine immunogène recombinante (pE(A)) ou des variants tronqués de celle-ci basés sur ladite protéine à surface exposée. L'invention concerne également des séquences d'acides nucléiques, des plasmides et des phages, des hôtes non humains, des séquences d'acides nucléiques recombinantes, des protéines hybrides et des produits hybrides. L'invention concerne en outre un procédé de production de ladite protéine ou des fragments tronqués de celle-ci par recombinaison.
MA31171A 2006-01-17 2008-08-12 NOUVELLE PROTEINE DE HAEMOPHILUS INFLUENZAE A SURFACE EXPOSEE (PROTEINE; pE) MA30309B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75898706P 2006-01-17 2006-01-17

Publications (1)

Publication Number Publication Date
MA30309B1 true MA30309B1 (fr) 2009-04-01

Family

ID=38287906

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31171A MA30309B1 (fr) 2006-01-17 2008-08-12 NOUVELLE PROTEINE DE HAEMOPHILUS INFLUENZAE A SURFACE EXPOSEE (PROTEINE; pE)

Country Status (20)

Country Link
US (5) US8617565B2 (fr)
EP (1) EP1973933B1 (fr)
JP (3) JP5275814B2 (fr)
KR (2) KR20080096775A (fr)
CN (2) CN101374859B (fr)
AU (1) AU2007206114B2 (fr)
BR (1) BRPI0707154B8 (fr)
CA (1) CA2636566C (fr)
EA (1) EA015561B1 (fr)
ES (1) ES2809167T3 (fr)
IL (2) IL192674B (fr)
MA (1) MA30309B1 (fr)
MX (1) MX2008009280A (fr)
MY (1) MY150105A (fr)
NO (1) NO346497B1 (fr)
NZ (1) NZ569417A (fr)
SG (2) SG10201600336RA (fr)
UA (1) UA92782C2 (fr)
WO (1) WO2007084053A1 (fr)
ZA (1) ZA200805602B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2548884B1 (fr) 2005-08-10 2017-08-02 Arne Forsgren AB Interaction de moraxella catarrhalis avec des cellules épithéliales, des protéines matricielles extracellulaires et le système compleméntaire
UA92782C2 (ru) * 2006-01-17 2010-12-10 Арне Форсгрен Новый поверхностный белок haemophilus influenzae (белок е; ре)
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
CA2835510A1 (fr) * 2011-05-11 2012-11-15 Riesbeck Healthcare Sweden Ab Proteine f : nouvelle adhesine haemophilus influenzae ayant des proprietes de liaison a la laminine et a la vitronectine
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
WO2014060383A1 (fr) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Composition immunogène comprenant un ou plusieurs conjugués saccharides capsulaires de streptococcus pneumoniae et un constituant protéique comprenant la protéine e et/ou pila d'haemophilus influenzae
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
US11167022B2 (en) 2017-03-31 2021-11-09 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US12016919B2 (en) 2017-05-30 2024-06-25 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2019034575A1 (fr) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa Procédés d'amplification des réponses immunitaires
CA3083078A1 (fr) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Purification de saponine
CN108037277A (zh) * 2017-12-07 2018-05-15 中国兽医药品监察所 一种区分牛布鲁氏菌疫苗免疫与自然感染状态的方法
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
EP3886901A1 (fr) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Procédés de fabrication d'un adjuvant
EP3953380A4 (fr) * 2019-04-12 2023-01-25 Geltor, Inc. Élastine de recombinaison et production associée
JP2022535091A (ja) 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
US20230066762A1 (en) 2019-08-05 2023-03-02 Glaxosmithkline Biologicals Sa Immunogenic composition
AU2020325569B2 (en) 2019-08-05 2024-01-18 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein D polypeptide
WO2022175423A1 (fr) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Composition immunogène, utilisation et procédés
WO2024017827A1 (fr) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Procédé continu de production de vaccin

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE205534T1 (de) 1988-12-16 2001-09-15 Nederlanden Staat Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
ZA921025B (en) 1991-02-15 1992-11-25 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
CN1091138A (zh) 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
WO1994022914A1 (fr) 1993-04-06 1994-10-13 Fred Hutchinson Cancer Research Center Recepteurs de cytokine chimeriques dans des lymphocytes
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
WO1994029458A1 (fr) 1993-06-07 1994-12-22 Amgen Inc. Molecules receptrices hybrides
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2717081B1 (fr) 1994-03-14 1996-06-21 Centre Nat Rech Scient Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
BR9609399A (pt) 1995-06-07 2001-08-28 Biochem Vaccines Inc Elementos de proteìnas de choque térmico estreptocócicos da famìlia hsp70
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
DE69737125T3 (de) 1996-10-31 2015-02-26 Human Genome Sciences, Inc. Streptococcus pneumoniae-Antigene und Impfstoffe
JP2001502925A (ja) 1997-06-03 2001-03-06 コノート ラボラトリーズ リミテッド モラクセラのラクトフェリン受容体遺伝子
WO1999003884A2 (fr) 1997-07-21 1999-01-28 North American Vaccine, Inc. Compositions de pneumolysine immunogene modifiee utiles en tant que vaccins
NZ530277A (en) 1998-04-07 2005-08-26 Medimmune Inc Derivatives of pneumococcal choline binding proteins for vaccines
AU770378B2 (en) 1998-04-23 2004-02-19 Uab Research Foundation Pneumococcal surface protein C(PspC), epitopic regions and strain selection thereof, and uses therefor
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
HU228499B1 (en) * 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0003502D0 (en) 2000-02-15 2000-04-05 Smithkline Beecham Sa Vaccine
CZ20024224A3 (cs) * 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
US20040171802A1 (en) * 2000-10-02 2004-09-02 Josee Hamel Haemophilus influenzae antigens and corresponding dna fragments
GB0025171D0 (en) 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
GB0025170D0 (en) 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
GB0025998D0 (en) 2000-10-24 2000-12-13 Smithkline Beecham Biolog Novel compounds
GB0410866D0 (en) * 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
UA92782C2 (ru) 2006-01-17 2010-12-10 Арне Форсгрен Новый поверхностный белок haemophilus influenzae (белок е; ре)
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
WO2007084053A1 (fr) 2007-07-26
SG175492A1 (en) 2011-11-28
US20140350220A1 (en) 2014-11-27
EA015561B1 (ru) 2011-08-30
NO20082827L (no) 2008-10-17
BRPI0707154B1 (pt) 2019-05-07
CN104436180B (zh) 2021-08-31
IL192674A0 (en) 2009-02-11
JP6008747B2 (ja) 2016-10-19
ES2809167T3 (es) 2021-03-03
CN101374859A (zh) 2009-02-25
US20150071956A1 (en) 2015-03-12
IL259316B (en) 2022-10-01
BRPI0707154A2 (pt) 2011-04-26
CA2636566C (fr) 2018-03-13
US20090246219A1 (en) 2009-10-01
US8617565B2 (en) 2013-12-31
SG10201600336RA (en) 2016-02-26
BRPI0707154B8 (pt) 2022-12-20
JP2009523790A (ja) 2009-06-25
JP2016135770A (ja) 2016-07-28
CN101374859B (zh) 2014-11-26
IL259316A (en) 2018-07-31
IL192674B (en) 2018-08-30
KR20140101387A (ko) 2014-08-19
EP1973933B1 (fr) 2020-06-24
JP5275814B2 (ja) 2013-08-28
US11400148B2 (en) 2022-08-02
MX2008009280A (es) 2008-12-12
EA200870176A1 (ru) 2009-06-30
US20170326223A1 (en) 2017-11-16
UA92782C2 (ru) 2010-12-10
KR20080096775A (ko) 2008-11-03
NO346497B1 (no) 2022-09-05
EP1973933A4 (fr) 2010-04-07
NZ569417A (en) 2012-04-27
JP2013126986A (ja) 2013-06-27
EP1973933A1 (fr) 2008-10-01
US9309293B2 (en) 2016-04-12
CN104436180A (zh) 2015-03-25
KR101737464B1 (ko) 2017-05-18
AU2007206114A1 (en) 2007-07-26
ZA200805602B (en) 2009-12-30
IL259316B2 (en) 2023-02-01
CA2636566A1 (fr) 2007-07-26
AU2007206114B2 (en) 2013-01-24
US20160114021A1 (en) 2016-04-28
MY150105A (en) 2013-11-29
US9744225B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
MA30309B1 (fr) NOUVELLE PROTEINE DE HAEMOPHILUS INFLUENZAE A SURFACE EXPOSEE (PROTEINE; pE)
EP3552622A3 (fr) Amorçage d'une réponse immunitaire
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
NZ592009A (en) Fgf21 mutants and uses thereof
NZ595499A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
EP4365196A3 (fr) Compositions concernant une toxine mutante de clostridium difficile et procédés associés
MX343744B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
WO2007106476A3 (fr) Compositions et procédés pour renforcer l'immunogénicité d'antigènes
MXPA06008217A (es) Vacunas con subunidad de lawsonia intracellularis.
JP2012515557A5 (fr)
GB0711424D0 (en) Recombinant transferrin mutants
WO2007064844A3 (fr) Composes de griffithsin antiviraux, compositions, et procedes d'utilisation correspondants
JP2014507146A5 (fr)
TW200716166A (en) Lawsonia intracellularis immunological proteins
DE602007012343D1 (de) Antimykotische polypeptide
UA103885C2 (en) Immunogenic streptococcus proteins
WO2003066820A3 (fr) Molecules d'acides nucleiques codant pour des proteines de ciblage endosomales derivees de cd1 et utilisations associees
WO2009066462A1 (fr) Procédé pour l'induction d'un lymphocyte t cytotoxique, inducteur de lymphocyte t cytotoxique et composition pharmaceutique et vaccin comprenant chacun l'inducteur
EA200901441A1 (ru) Новые молекулы антител и нуклеиновых кислот, связывающиеся с грибным белком теплового шока hsp90
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
WO2006113782A3 (fr) Proteine lawsonia utilisee comme composant dans un vaccin sous-unite et procedes de fabrication et d'utilisation associes
MX2010010025A (es) Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
JP2009524413A5 (fr)
HRP20161225T1 (hr) Marker cjepivo za klasičnu svinjsku groznicu